Yesterday, FDA Acting Commissioner Stephen Ostroff, M.D. spoke at the RAPS Regulatory Convergence, where he highlighted various events leading to the transformation taking place within the Agency.
During his address, he confessed the Agency is “in uncharted territory,” and advised everyone to “stay tuned”. Currently, a lot is going on within FDA –the transition between commissioners and user fee negotiations, for example. Outside of the Agency there a number of activities that will have a direct impact on FDA – including significant pending legislation.
In the midst of this whirlwind, FDA has continued to introduce and make progress on new initiatives. One that Commissioner Ostroff drew particular attention to is the ‘patient-centric’ approach the Agency launched. He outlined specific actions taken by FDA in order to execute this new approach, highlighting the first-ever Patient Engagement Advisory Committee (PEAC). The PEAC was recently introduced by FDA’s Center for Devices and Radiological Health (CDRH) for the purpose of helping ensure that patient needs and experiences are included, and taken into consideration, during the review of medical devices. He added that “meaningful patient engagement ‘is not without its challenges,’” and provided specific examples, such as patients’ understanding of the regulatory framework and clinical trial design, as well as the exorbitant number of patient perspectives that FDA has had to manage.
Ostroff referenced various conversations in which people “insist that fewer regulations are always conducive to a better business environment.” To this he responded by emphasizing the importance of preserving FDA’s role as “the protector of the American public.”
Finally, he concluded his address stating that “we must not shortchange the standards that have provided safe and effective medical products.”
February 22, 2016
On Tuesday, February 16, FDA announced the publication of a guidance that provides blood establishments with recommendations to reduce the risk of contaminating the US blood supply with the Zika...
January 5, 2016
In December 2015, the FDA released a draft guidance, which provides IND sponsors with a number of recommendations and best practices for communicating with the FDA. Among those included in the draft...
March 21, 2016
FDA’s Proposed Study on Consumer Understanding of Quantitative Information in DTC Drug Ads In October 2015, the FDA announced plans to conduct a study which would determine how much quantitative...